stockrow
Thursday 5 November 2026
Export TLSA’s income statement to Excel — free account
Tiziana Life Sciences Ltd
TLSA Healthcare Biotechnology
0.62
0.02
−3.13%
Follow TLSA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.0 pt | ||||||
| EBT | (10) | (11) | (10) | (10) | (28) | (27) | (15) | (17) | (17) | (18) | +7.2% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (10) | (11) | (10) | (10) | (28) | (27) | (15) | (17) | (17) | (18) | +7.2% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.22) | (0.16) | (0.12) | (0.34) | (0.27) | (0.24) | (0.15) | (0.17) | (0.11) | (0.16) | (3.5%) | ||||||
| Cash flow | (0.16) | (0.14) | (0.07) | (0.25) | (0.12) | (0.22) | (0.19) | (0.15) | (0.01) | (0.11) | (3.9%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (17.3%) | ||||||
| Free cash flow | (0.16) | (0.14) | (0.07) | (0.25) | (0.12) | (0.22) | (0.19) | (0.15) | (0.01) | (0.11) | (4.0%) | ||||||
| Book value | 0.09 | (0.04) | 0.01 | (0.20) | 0.64 | 0.42 | 0.19 | 0.05 | 0.04 | 0.00 | (45.4%) | ||||||
| Shares, m | 44 | 53 | 64 | 27 | 97 | 98 | 103 | 104 | 107 | 118 | +11.5% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (7) | (8) | (5) | (7) | (11) | (22) | (20) | (16) | (2) | (13) | +7.1% | |||||
| Capex | 0 | 0 | — | 0 | 0 | 0 | — | — | 0 | 0 | (8.8%) | ||||||
| Free cash flow | (7) | (8) | (5) | (7) | (11) | (22) | (20) | (16) | (2) | (13) | +7.0% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 4 | (2) | 1 | (6) | 62 | 41 | 18 | 1 | 0 | (3) | n/m | |||||
| Net debt | (5) | 0 | (5) | 1 | (65) | (42) | (18) | (1) | (4) | (4) | (3.4%) | ||||||
| Shareholders’ equity | 4 | (2) | 1 | (6) | 62 | 41 | 20 | 6 | 4 | 0 | (38.4%) | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (97.94) | (200.32) | (168.97) | (200.54) | (71.56) | (39.20) | (40.89) | (91.52) | (101.10) | (161.82) | (63.9) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (629.14) | (258.21) | (4,656.25) | 0.00 | 0.0 pt | ||||||
| ROE | 1,282.91 | (963.09) | 902.10 | 373.29 | (91.89) | (45.18) | (50.61) | (140.92) | (250.49) | (924.32) | (2,207.2) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | 8 | 9 | 8 | 11 | 14 | 9 | 9 | 9 | 10 | +2.8% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Tiziana Life Sciences Ltd vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GNLX Genelux Corporation | $88.7M | — (loss-making) | — (loss-making) | — | n/m | −11.18% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TNXP Tonix Pharmaceuticals Holding Corp. | $87.6M | — (loss-making) | — (loss-making) | +577.88% (above 0%: growing) | n/m | −178.84% (below 0%: shrinking) | 94.81% | (314.05%) | Compare |
| NRXS Neuraxis, Inc. | $86.2M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| RLYB Rallybio Corporation | $85.6M | 3.3× | — (loss-making) | 0.00% | n/m | +65.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CLLS Cellectis S.A. | $84.6M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| TNYA Tenaya Therapeutics, Inc. | $84.3M | — (loss-making) | — | — | n/m | −13.18% (below 0%: shrinking) | 100.00% | (1,153.33%) | Compare |
| ATRA Atara Biotherapeutics, Inc. | $84.0M | — (loss-making) | — (loss-making) | −96.42% (below 0%: shrinking) | n/m | +52.10% (above 0%: growing) | 69.68% | (749.21%) | Compare |
| TLSA Tiziana Life Sciences Ltd | $81.9M | — (loss-making) | — | — | −258.11% (below 0%: shrinking) | +18.03% (above 0%: growing) | 0.00% | — | |
| RANI Rani Therapeutics Holdings, Inc. | $79.9M | — (loss-making) | — (loss-making) | 0.00% | n/m | −55.29% (below 0%: shrinking) | 100.00% | (516.86%) | Compare |
| Median of peers | $85.1M | — | — | 0.00% | — | −12.18% | 100.00% | (327.37%) |